Early Phase 1 Interstitial Lung Disease Trial, Recruiting (NCT05365802)

Early Phase 1 Interstitial Lung Disease Trial, Recruiting NCT05365802 Sponsor: University of California, Los Angeles Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05365802 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a lung condition called ILD (interstitial lung disease), confirmed by a CT scan at the time of their diagnosis or staging
People who have recently started, or are about to start, a new medication for ILD within 3 months of joining the trial, OR people who are scheduled to have a tissue sample (biopsy) or surgery on their lung
People who are 18 years of age or older at the time of receiving the imaging agent used in the trial
People who are able to give written consent to participate

Who may not be able to join:

People who are pregnant or breastfeeding
People who currently have an active infectious disease affecting the lungs
People who are not expected to be able to follow the trial's requirements, or who are unable to understand or follow the trial procedures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Jeremie Calais, MD, Clinical Research Director, Ahmanson Translational Theranostics

Phone: 3102067372

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05365802

Sponsor: University of California, Los Angeles

Phase: Early Phase 1

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: 3102067372

More information: https://clinicaltrials.gov/study/NCT05365802

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a lung condition called ILD (interstitial lung disease), confirmed by a CT scan at the time of their diagnosis or staging
People who have recently started, or are about to start, a new medication for ILD within 3 months of joining the trial, OR people who are scheduled to have a tissue sample (biopsy) or surgery on their lung
People who are 18 years of age or older at the time of receiving the imaging agent used in the trial
People who are able to give written consent to participate

Who may not be able to join:

People who are pregnant or breastfeeding
People who currently have an active infectious disease affecting the lungs
People who are not expected to be able to follow the trial's requirements, or who are unable to understand or follow the trial procedures

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Early Phase 1

Sponsor

University of California, Los Angeles

Registry

ClinicalTrials.gov

Start date

16 November 2021

Est. completion

1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) in patients with Interstitial Lung Disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov